Last reviewed · How we verify
Allocetra
At a glance
| Generic name | Allocetra |
|---|---|
| Sponsor | Enlivex Therapeutics Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Intra-articular Allocetra in Knee Osteoarthritis (PHASE1, PHASE2)
- Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis (PHASE1)
- A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients (PHASE2)
- Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety (EARLY_PHASE1)
- Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ) (PHASE1)
- Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint (PHASE1, PHASE2)
- A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy (PHASE1, PHASE2)
- Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allocetra CI brief — competitive landscape report
- Allocetra updates RSS · CI watch RSS
- Enlivex Therapeutics Ltd. portfolio CI